CA2014208A1 - Blocage selectif de neurones dopaminergiques a action spontanee de la region tegumentaire ventrale - Google Patents

Blocage selectif de neurones dopaminergiques a action spontanee de la region tegumentaire ventrale

Info

Publication number
CA2014208A1
CA2014208A1 CA2014208A CA2014208A CA2014208A1 CA 2014208 A1 CA2014208 A1 CA 2014208A1 CA 2014208 A CA2014208 A CA 2014208A CA 2014208 A CA2014208 A CA 2014208A CA 2014208 A1 CA2014208 A1 CA 2014208A1
Authority
CA
Canada
Prior art keywords
spontaneously
ventral tegmental
tegmental area
dopamine neurones
selective blocking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2014208A
Other languages
English (en)
Other versions
CA2014208C (fr
Inventor
Jens Perregaard
Torben Skarsfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2014208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2014208A1 publication Critical patent/CA2014208A1/fr
Application granted granted Critical
Publication of CA2014208C publication Critical patent/CA2014208C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
CA002014208A 1989-04-11 1990-04-09 Blocage selectif de neurones dopaminergiques a action spontanee de la region tegumentaire ventrale Expired - Lifetime CA2014208C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use
GB8908085.7 1989-04-11

Publications (2)

Publication Number Publication Date
CA2014208A1 true CA2014208A1 (fr) 1990-10-11
CA2014208C CA2014208C (fr) 1996-03-19

Family

ID=10654774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002014208A Expired - Lifetime CA2014208C (fr) 1989-04-11 1990-04-09 Blocage selectif de neurones dopaminergiques a action spontanee de la region tegumentaire ventrale

Country Status (18)

Country Link
US (1) US5112838A (fr)
EP (1) EP0392959B1 (fr)
JP (1) JP2775191B2 (fr)
KR (1) KR920008703B1 (fr)
AT (1) ATE157005T1 (fr)
AU (1) AU621735B2 (fr)
CA (1) CA2014208C (fr)
CY (1) CY2082B1 (fr)
DE (2) DE19875011I2 (fr)
DK (1) DK0392959T3 (fr)
GB (1) GB8908085D0 (fr)
HK (1) HK1002825A1 (fr)
IE (1) IE81157B1 (fr)
IL (1) IL94021A (fr)
NL (1) NL980008I1 (fr)
NZ (2) NZ243765A (fr)
SG (1) SG48234A1 (fr)
ZA (1) ZA902785B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1997035584A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Procede de traitement de la douleur
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
CN1281335A (zh) * 1997-10-27 2001-01-24 科泰克斯药物股份有限公司 用安哌克和精神安定剂治疗精神分裂症
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
CA2468972A1 (fr) * 2001-12-10 2003-07-03 Novartis Ag Methodes de traitement de la psychose et la schizophrenie fondees sur unpolymorphisme du gene cntf
IL163992A0 (en) * 2002-03-27 2005-12-18 Lundbeck & Co As H Method for manufacture of sertindole
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005102366A2 (fr) * 2004-04-19 2005-11-03 Philip Maxwell Satow Combinaisons de lithium et utilisations associees
WO2005107808A2 (fr) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht1b
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
CA2609185A1 (fr) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Procede de fabrication de derives de sulfamide
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
EP2026790A2 (fr) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (fr) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Génotypes rgs2 associés aux symptômes extrapyramidaux induits par un médicament antipsychotique
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
WO2008106144A2 (fr) * 2007-02-28 2008-09-04 Nupathe Inc. Implants destinés au traitement d'états psychiatriques
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
WO2009156889A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composés diaryle et leurs utilisations
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Also Published As

Publication number Publication date
AU621735B2 (en) 1992-03-19
EP0392959B1 (fr) 1997-08-20
KR920008703B1 (ko) 1992-10-08
IL94021A0 (fr) 1991-01-31
KR900015730A (ko) 1990-11-10
GB8908085D0 (en) 1989-05-24
CY2082B1 (en) 1998-10-16
IE81157B1 (en) 2000-05-03
DE69031290D1 (de) 1997-09-25
JPH02290872A (ja) 1990-11-30
NZ233179A (en) 1996-12-20
CA2014208C (fr) 1996-03-19
EP0392959A3 (fr) 1992-05-06
DK0392959T3 (da) 1999-03-29
ZA902785B (en) 1991-06-26
AU5303790A (en) 1990-10-18
SG48234A1 (en) 1998-04-17
DE69031290T2 (de) 1998-01-02
IE901051L (en) 1990-10-11
HK1002825A1 (en) 1998-09-18
NL980008I1 (nl) 1998-05-06
US5112838A (en) 1992-05-12
IL94021A (en) 1994-01-25
NZ243765A (en) 1997-09-22
ATE157005T1 (de) 1997-09-15
JP2775191B2 (ja) 1998-07-16
EP0392959A2 (fr) 1990-10-17
DE19875011I2 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
CA2014208A1 (fr) Blocage selectif de neurones dopaminergiques a action spontanee de la region tegumentaire ventrale
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
IE894048L (en) New therapeutically active compound and a process for its¹preparation
AU599792B2 (en) Anti-parkinsonian indolone derivatives
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ATE255410T1 (de) Arzneimittel, das clodronat als wirkstoff und mit siliciumdioxid behandelte mikrokristalline cellulose als füllstoff enthält
WO2003015779A3 (fr) Systeme therapeutique transdermique a regulation matricielle permettant l'administration de pramipexol et de ropinirol
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
NZ237309A (en) 1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
NO167204C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diacylderivater av 4-(trialkylbenzyl)-piperazinylforbindelser.
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
NO167456C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 7-(3-amino-1-pyrrolidinyl)-8-brom-1-syklopropyl-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
NO891046D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2,4-triazol-derivater.
NO893784D0 (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktiveimidazolderivater.
PT855398E (pt) Derivados sasquiterpeno tendo actividade antiviral
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE69000806D1 (de) Indol-derivate.
CA2154485A1 (fr) Composition pharmaceutique renfermant la 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone et son emploi pour le traitement des troubles du snc
NO882279D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive endo-bicyklo (2,2,1) heptyl-adenosin-derivater.
NO890328L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 4-amino-2,3-disubstituert-6,7-dihydro-5h-1-pyrindinderivater.
NO883932D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive laktamderivater.
IT8619931A0 (it) Procedimento per la preparazione della 1-(n-metilamidino)-3-(2,6-dimetilfe nil) urea e dei suoi sali farmaceuticamente accettabili.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry